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Introduction
Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignancy in the world and the fourth leading 
cause of cancer death in the United States [1, 2]. Surgical 
resection and transplantation are potentially curative treat-
ments for HCC, but only 10–15% of patients are candidates 
[1, 2]. The overall survival (OS) benefits from current 
liver- directed transcatheter approaches remain relatively 
modest [2–4].
While natural killer (NK) cell- based adoptive transfer 
immunotherapy (ATI) holds great promise for clinical 
cancer treatment, only modest clinical success has been 
achieved thus far using NK- ATI therapies in cancer patients 
[5, 6]. Two challenges hurdle for NK- ATI in HCC patients 
include: (1) inadequate homing efficiency of NKs to the 
targeted tumors and (2) lack of well- established nonin-
vasive tools for predicting the NK- ATI response [7–9].
We used a clinically applicable approach combining 
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Abstract
While natural killer (NK) cell- based adoptive transfer immunotherapy (ATI) 
provides only modest clinical success in cancer patients. This study was hy-
pothesized that MRI- guided transcatheter intra- hepatic arterial (IHA) infusion 
permits local delivery to liver tumors to improve outcomes during NK- based 
ATI in a rat model of hepatocellular carcinoma (HCC). Mouse NK cells were 
labeled with clinically applicable iron nanocomplexes. Twenty rat HCC models 
were assigned to three groups: transcatheter IHA saline infusion as the control 
group, transcatheter IHA NK infusion group, and intravenous (IV) NK infusion 
group. MRI studies were performed at baseline and at 24 h, 48 h, and 8 days 
postinfusion. There was a significant difference in tumor R2* values between 
baseline and 24 h following the selective transcatheter IHA NK delivery to the 
tumors (P = 0.039) when compared to IV NK infusion (P = 0.803). At 8 days 
postinfusion, there were significant differences in tumor volumes between the 
control, IV, and IHA NK infusion groups (control vs. IV, P = 0.196; control 
vs. IHA, P < 0.001; and IV vs. IHA, P = 0.001). Moreover, there was a strong 
correlation between tumor R2* value change (∆R2*) at 24 h postinfusion and 
tumor volume change (∆volume) at 8 days in IHA group (R2 = 0.704, P < 0.001). 
Clinically applicable labeled NK cells with 12- h labeling time can be tracked 
by MRI. Transcatheter IHA infusion improves NK cell homing efficacy and 
immunotherapeutic efficiency. The change in tumor R2* value 24 h postinfusion 
is an important early biomarker for prediction of longitudinal response.
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ferumoxytol to form HPF nanocomplexes for magnetic 
NK labeling so that NK cell biodistribution could be 
visualized in vivo with advanced magnetic resonance imag-
ing (MRI) following transcatheter intrahepatic arterial 
(IHA) local delivery.
The purposes of our study was to test the hypotheses 
in a rat model of hepatocellular carcinoma: (1) clinically 
applicable labeled NK cells can be tracked with MRI, (2) 
transcatheter IHA NK infusion improves NK cell homing 
efficacy to targeted tumors, and (3) serial MRI monitoring 
of NK cell migration to targeted tumors can serve as an 
early biomarker for prediction of longitudinal response.
Materials­and­Methods
All studies were approved by our institutional animal care 
and use committee and were performed in accordance 
with the NIH guidelines.
Cell­lines­and­culture
Mouse NK cell line (LNK) [10] was kindly obtained by 
Stephen K. Anderson (National Cancer Institute, Frederick, 
MD). The LNK cell line was cultured in RPMI 1640 
containing 10% fetal bovine serum (FBS), 100 U/mL 
penicillin, 100 U/mL streptomycin, 1.5 g/L sodium pyru-
vate, l- glutamine, and IL- 2 (8000 IU/mL) at 37°C in a 
humidified atmosphere with 5% CO2 air. McA- RH7777 
(McA) is buffalo rat hepatoma cell line (ATCC, CRL- 1601, 
Manassas, VA) [11] was cultured in Dulbecco’s modified 
Eagle’s medium (DMEM, ATCC, Manassas, VA) contain-
ing 10% FBS, 100 U/mL penicillin, and 100 U/mL strep-
tomycin at 37°C with 5% CO2 air. Trypan blue staining 
was performed before each tumor implantation procedure 
to verify >90% cell viability.
HPF­nanocomplex­preparation
FDA- approved ferumoxytol (Feraheme®, AMAG 
Pharmaceuticals, Inc., Boston, MA) is an ultra- small super-
paramagnetic iron oxide nanoparticle with a size of 
17–31 nm in diameter for treatment of iron deficiency 
anemia. FDA- approved heparin sulfate and protamine sulfate 
(both from American Pharmaceuticals Partner, IL) were 
used to form HPF nanocomplexes [12]. The HPF complexes 
were prepared by sequentially adding heparin at 2 U/mL 
and protamine at 60 μg/mL with ferumoxytol at 50, 100, 
or 200 μg/mL, separately [12, 13] (L.Z., B.W., and Z.Z).
HPF­nanocomplex­labeling­of­LNKs
HPF nanocomplexes (with 0, 50, 100, or 200 μg/mL feru-
moxytol) in 0.5 mL phosphate- buffered saline (PBS) were 
added to each flask (5 × 106 LNKs in 10 mL culture 
medium), separately. Each flask was then incubated for 
12 h. Labeled cells were harvested and washed with PBS 
and then with 10 U/mL heparin to remove the residual 
HPF [12]. Cells were then fixed for Prussian blue 
(Invitrogen, Carlsbad, CA) staining and transmission elec-
tronic microscopy (TEM) (FEI Company, Hillsboro, OR). 
Cell labeling efficiency (%) = number of positive- staining 
cells/number of total cells in per ten fields (20×) (S.Z. 
and Z.Z.). TEM images of LNKs were used to verify 
intracellular iron uptake. A separate set of samples was 
used to quantify iron content within each cell using induc-
tively coupled plasma mass spectrometry (ICP- MS, Thermo 
Fisher Scientific Inc., Waltham, MA), as previously 
described [14] (L.Z. and Z.Z.).
Labeled­NK­cell­viability­and­cytotoxicity­
function­assays
The cell viability assay methods were described in previ-
ous studies [14, 15]. Aliquots with 5 × 105 cells each 
were resuspended in 100 μL annexin V binding buffer 
(BD Pharmingen, San Diego, CA) and incubated with 
5 μL FITC- conjugated annexin V reagent (BD Pharmingen), 
either with or without 10 μL of 50 μg/mL propidium 
iodide solution (PI, BD Pharmingen) for 15 min in the 
dark. These cells were then analyzed using a FACScalibur 
flow cytometer (BD Biosciences, San Jose, CA), yielding 
percentages of apoptotic (annexin V positive, PI negative), 
necrotic, and viable cells. The study was repeated with 
0, 50, 100, or 200 μg/mL ferumoxytol labeling protocol, 
and cell viabilities were assessed at 3 days after the 12 h 
labeling period (each group, N = 6).
NK cells were labeled with HPF nanocomplexes (50 μg 
HPF/mL with 106 NK cells for 12 h labeling). McA target 
cells were labeled with carboxyfluorescein succinimidyl 
ester (CFSE, Sigma- Aldrich, St. Louis, MO) to discriminate 
target cells from effector cells. Labeled and unlabeled or 
HPF- labeled NK effector cells were co- cultured with CFSE 
labeled McA target cells at different effectors to target 
(E/T) ratios at 25:1, 12.5:1, and 6.2:1 in 96- well U- bottomed 
microplates, separately. Additionally, two sets of controls 
containing only effector cells or only target cells were 
prepared. After overnight co- culture, the cells were har-
vested and stained with 7- AAD (BD Pharmingen) and 
pacific blue Annexin V for 15 min in the dark. These 
cells were then analyzed using a FACScalibur flow cytom-
eter. All conditions were performed five times indepen-
dently. NK cytotoxicity (%) is calculated as the number 
of cells positive for both CFSE and Annexin V divided 
by the total number of CFSE positive cells, after subtract-
ing the spontaneous apoptosis (%) in target cell only 
controls (B.W., B.Z., Z.Z., and L.Q.) [16].
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Animal­model
Twenty male buffalo rats (body weight 250–300 g, Charles 
River Laboratories, Wilmington, MA) were anesthetized. A 
mini- laparotomy was performed, and 2 × 106 McA cells 
in 0.2 mL PBS were injected in the left median and left 
lateral lobes. Tumors were allowed to grow for 7 days to 
reach a size typically ≥5 mm in diameter verified by MRI. 
These rats were separated into three groups: transcatheter 
IHA saline infusion as the control group, transcatheter IHA 
LNK infusion group, and intravenous (IV) LNK infusion 
group (each group N = 6, 12 tumors, a total of 36 tumors 
included) (Z.S., T.L., X.W., M.F., and Z.Z.) [17, 18].
Transcatheter­IHA­LNK­local­infusion
Transcatheter IHA infusion methods were described in 
previous studies [17–19]. In brief, the rat was anesthetized, 
and a mini- laparotomy was performed. The common hepatic 
artery was clamped to temporarily prevent bleeding, and 
a 4- 0 suture was used to permanently ligate the gastroduo-
denal artery to prevent backwards flow. A 24- gauge micro-
catheter was placed in common branch of the proper hepatic 
artery with placement confirmed by digital subtraction 
angiography (DSA) guidance (Omnipaque, GE Healthcare, 
Pittsburgh, PA). Catheter was placed in the left hepatic 
artery, and 0.1 mL of heparin was infused before infusing 
4.0 × 106 labeled LNKs (50 μg/mL HPF labeling 12 h) 
suspended in 0.3 mL PBS. After LNK infusion, abdominal 
incisions were closed. For the transcatheter IHA saline infu-
sion control group, 0.5 mL of PBS was infused, comparable 
in volume to the LNK suspension. All other procedures 
were done by the exact same method as transcatheter IHA 
LNK infusion group (Z.S., T.L., X.W., M.F., and Z.Z.).
IVLNK­systemic­delivery
4 × 106 labeled LNKs (50 μg/mL HPF labeling 12 h) in 
0.5 mL of PBS were infused via tail vein followed by 
0.2 mL of saline flush and 0.1 mL of heparin lock flush.
MRI­of­cell­phantoms
MRI was performed using a 7.0 T 30 cm bore scanner 
(ClinScan, Bruker BioSpin, Ettlingen, Germany) with 75 mm 
rat coil (Bruker BioSpin). MRI sequences and parameters 
are listed in Table 1. Labeled cells using 50 μg/mL HPF 
labeling for 12 h were fixed with 10% formalin. LNK cell 
phantoms contained 1 × 106 and 2 × 106 labeled LNKs, 
2 × 106 unlabeled LNKs, or only 1% agarose. All cells were 
homogenously suspended in 1 mL 1% agarose gel (each 
N = 6). These mixtures were then transferred to 1.5 mL 
tubes for MR phantom studies (D.P., L.Z., and Z.Z.).
In­vivo­MRI­tracking­of­labeled­LNK­cell­
biodistribution­in­rat­liver
MRI scans were performed before (baseline) and at 24 h, 
48 h, and 8 days after injection using the 7.0 T scanner 
with 75 mm rat coil. T2 and T2*/R2* mapping was per-
formed following acquisition of TSE T1- weighted (T1W) 
and T2W anatomical images. Scan parameters are listed 
in Table 1. Mean R2* (1/T2*) values for the tumors were 
measured pre- and postinfusion of LNKs (24 h and 48 h) 
(M.F., X.W., and S.Z.).
Assessment­of­therapeutic­response­using­
T2W­images
The volume of each tumor was measured on axial T2W 
images as previously described [20]. These measurements 
were performed for both baseline images and images col-
lected at 8 days postinfusion. The change of tumor volume 
(∆volume) was calculated using the formula: 
∆volume = volume 8 days − volume at baseline (Z.S. 
and X.W.).
Histology
After completion of MRI 8 days postinfusion, all rats 
were euthanized. Livers were harvested and fixed in 10% 
Table 1. MRI sequences and parameters.
Sequence
Cell phantom In vivo MRI
GRE T2*W GRE T2* map TSE anatomy GRE T2 map GRE T2* map




1300/(9.3, 18.6, 27.9, 
37.2)
400/(3.28, 6.14, 9.00, 
11.86)
FA 9° 30° T1W/T2W: 90°/180° 180° 90°
FOV (mm2) 45 × 45 57 × 57 60 × 60 60 × 60 60 × 60
Matrix 128 × 128 128 × 128 192 × 192 192 × 192 192 × 192
ST (mm) 0.30 1.5 1.0 1.0 1.0
VS (mm3) 0.35 × 0.35 × 0.30 0.45 × 0.45 × 1.50 0.31 × 0.31 × 1.00 0.31 × 0.31 × 1.00 0.31 × 0.31 × 1.00
FA, flip angle; FOV, field of view; GRE, Gradient echo sequences; TE, echo time; TR, repetition time; TSE, turbo spin echo; ST, slice thickness; VS: voxel 
size.
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formalin, and then, tissues were embedded in paraffin. 
Sections including tumor tissues were sliced (4 μm) for 
CD56 (Anti- CD56, Becton Dickinson, San Jose, CA) 
immunohistochemistry (IHC) staining [17]. Resulting his-
tology slides were reviewed by a pathologist at Pathology 
Core Facility (L.L., MD, who had more than 10 years of 
experience).
Image­analysis
For MRI examinations, image analyses were performed 
using MATLAB (2011a, MathWorks, Natick, MA). T2*/
R2* maps were generated. Using both the T2W MR Images 
as anatomical reference to identify the tumor boundaries, 
region of interest (ROI) was drawn to completely cover 
the viable tumors to measure R2* values; four slices were 
included for each tumor for R2* measurements. ∆R2* 
values were calculated (∆R2* = tumor R2* at 24 h postin-
fusion − tumor R2* at baseline) (X.W. and Z.S.). CD56 
stained slides (4 slices/each tumor) were scanned at a 
magnification of 20× and digitized using the TissueFAXS 
system (TissueGnostics, Los Angeles, CA). These acquired 
images were analyzed using the HistoQuest Cell Analysis 
Software (TissueGnostics) package to quantify the total 
number of LNK cells within each specimen (T.L., X.W., 
and Z.S.).
Statistical­analysis
Data are presented as mean ± standard deviation (SD) 
as indicated. One- way ANOVA was used to compare in 
vivo R2* and tumor volume among animal groups (con-
trol, IHA, and IV) at baseline. t- tests were used to compare 
R2* and tumor volume of different groups measured at 
different time- points (baseline, 24 h, 48 h, and 8 days 
after infusion). Changes of R2* (∆R2*) and tumor volume 
(∆volume) were also compared among groups at different 
time points using t- test. Pearson’s correlation coefficient 
(r) was also applied to assess the relationship between 
∆R2* measurements and ∆volume measurements. Statistical 
analysis was performed using SAS 9.4 (SAS Institute, Inc., 




Microscopic observation of Prussian blue- stained LNKs 
revealed extensive, nonuniform uptake of iron particles 
(Fig. 1A–D). The iron content of the unlabeled cells was 
significantly lower than that of the labeled cell groups 
(Fig. 1E). Labeling efficiency measurements using Prussian 
blue assays are 0% for control with HPF, 87 ± 7% for 
50 μg/mL HPF group, 92 ± 5% for 100 μg/mL HPF 
group, and 95 ± 11% for 200 μg/mL HPF group. Uptake 
of iron nanoparicles was confirmed in labeled LNKs, but 
was not observed in unlabeled LNKs by TEM (Fig. 2A). 
The internalization of iron nanoparticles in the cytoplasm 
was confirmed and was not observed in the LNK cell 
membrane (Fig. 1B–C) with 0, 50, 100, or 200 μg/mL.
NK­cell­viability­and­cytotoxicity­function
At 3 days after the 12- h labeling period, there were no 
significant differences in the percentages of apoptotic cells 
in all groups, while significant increases in percentages 
of necrotic cells were observed in 100 μg/mL and 200 μg/
Figure 1. Prussian blue staining of LNKs with 12- h labeling period, cell labeling efficiency, and iron content in each cell. A–D, representative Prussian 
blue- stained LNKs. A, unlabeled LNKs; B, labeled LNKs with 50 μg/mL HPF; C, labeled LNKs with 100 μg/mL HPF; and D, labeled LNKs with 200 μg/mL 
HPF. E, Cellular uptake efficiency increased with exposure to a higher concentration of HPF during labeling procedures (50 µg/mL HPF group vs. 100 
µg/mL HPF group, p = 0.1783; 50 µg/mL HPF group vs. 200 µg/mL HPF group, p = 0.0535; 100 µg/mL HPF group vs. 200 µg/mL HPF group, p = 
0.3916).  F, cellular iron concentration (pg/cell) was measured by ICP- MS (each N = 6) (control vs. 50 μg/mL, P < 0.001; control vs. 100 μg/mL, 
P < 0.001; control vs. 200 μg/mL, P < 0.001; 50 μg/mL vs. 100 μg/mL, P = 0.178; 50 μg/mL vs. 200 μg/mL, P = 0.054; 100 μg/mL vs. 200 μg/mL, 
P = 0.392). A–D scale bars = 10 μm.
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Figure 2. Representative TEM images. A, TEM images of a single unlabeled LNK; B, a single HPF- labeled LNK using 50 μg/mL HPF with 12- h labeling 
period. TEM images demonstrated the localization of iron oxide particles within the cytoplasm and cytoplasmic vesicles of LNK cell (B), and C a 
magnified view of the square area in B.
Figure 3. LNK cell viability and assessments at day 3 after the 12- h labeling period and cytotoxicity assessments (each N = 6). A, a significant increase 
in the percentage of cell death was found for 100 μg/mL and 200 μg/mL HPF labeled groups compared to control group (100 μg/mL vs. control, 
P < 0.001; 200 μg/mL vs. control, P = 0.002); however, there was no significance between 50 μg/mL group and control group (P = 0.875). B, the 
percentage of apoptotic cells were measured by FACS, and there were no significant differences between unlabeled group and labeled groups 
(control vs. 50 μg/mL, P = 0.493; control vs. 100 μg/mL, P = 0.374; control vs. 200 μg/mL, P = 0.36; 50 μg/mL vs. 100 μg/mL, P = 0.659; 50 μg/mL 
vs. 200 μg/mL, P = 0.762; 100 μg/mL vs. 200 μg/mL, P = 0.831). C, NK cell killing of McA cells at three different effector to target ratios (E/T) (Group 
25/1: labeled and unlabeled, P = 0.19; Group 12.5/1, P = 0.579; Group 6.2/1, P = 0.267). D, representative flow dot plots of (C) at 25:1 (E/T).
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mL compared to control group F (Fig. 3A and B). For 
cytotoxicity function assay, there was no significant dif-
ference between labeled and unlabeled NK cells at all 
target effector ratios (Fig. 3C). The percentage of early 
apoptosis and late apoptosis of target cells caused by 
unlabeled and labeled NK cells also showed no significant 
difference at all ratios, and representative flow dot plots 
of (Fig. 3C) at 25:1 (E/T) are shown in Figure 3D.
In­vitro­MRI­of­phantoms
The T2* signal- to- noise ratio (SNR) of the LNK cell 
phantoms containing different numbers of LNKs labeled 
with 50 μg/mL HPF markedly decreased with increasing 
cell number (Fig. 4A). SNR values decreased in propor-
tion to the number of labeled LNKs included in each 
cell phantom in Figure 4B. R2* values increased in pro-
portion to the number of labeled LNKs included in each 
cell phantom in Figure 4C.
In­vivo­quantitative­MRI­measurements
One rat displayed no growth (no tumor detected) and 
thus was excluded from the study. Another rat was excluded 
because of poor health at baseline imaging time- point.
Following tumor implantation at 7 days, tumor volume 
was measured in T2W images. The mean baseline tumor 
volumes for control, IV, and IHA groups were 
65.69 ± 18.10 mm3, 64.35 ± 18.26 mm3, and 
64.07 ± 11.53 mm3, respectively. The tumors were depicted 
with relatively homogeneous high signal intensity before 
the delivery of labeled NKs in baseline T2W and T2*W 
images. Representative axial T2W images, T2*W images, 
and R2* maps from one of the IHA group animals were 
shown (Fig. 5A).
Identification of the IHA and its subsequent catheteri-
zation was confirmed by DSA, and the success rate was 
100%. For IHA LNK group, both 24 h and 48 h postin-
fusion signal intensities within the tumor nodules became 
heterogeneous. Figure 5B shows: (1) There were no sig-
nificant differences in baseline tumor R2* values of the 
three groups. A significant difference in R2* values was 
found between baseline and 24/48 h after IHA LNK cell 
infusion within tumor tissues, but there was no significant 
difference in tumor R2* values between the 24 h and 
48 h follow- up period and (2) there were no significant 
differences in R2* values between baseline and 24/48 h; 
between 24 h and 48 h after IV LNK cell infusion, but 
increasing R2* value trends were observed between base-
line and 24/48 h. However, there were significant differ-
ences in tumor R2* values between control, IV, and IHA 
groups at both 24 h and 48 h postinfusion time- points 
(Fig. 5B).
Therapy­response­and­histology
The efficacy of the LNK cell therapy was evident as inhi-
bition of tumor growth in the IHA group when compared 
to that in control/IV animals 8 days after infusion (∆volume: 
control vs. IHA, P < 0.001; IV vs. IHA, P = 0.001). There 
were no significant differences in therapeutic responses 
between the control group and IV group animals 8 days 
after infusion (P = 0.196) (Fig. 6A). No significant dif-
ferences were observed in ∆volume between the control 
Figure 4. Qualitative MRI of cell phantoms (each N = 6). A, T2* signal intensity of the NK cell phantoms containing different numbers NKs labeled 
with 50 μg/mL HPF. B, SNR values decreased in proportion to the number of labeled NKs included in cell phantoms (agarose vs. 2- million unlabeled 
cells, P = 0.062; agarose vs. 1- million labeled cells, P = 0.001, agarose vs. 2- million labeled cells P < 0.001; 2- million unlabeled vs. 1- million labeled 
cells, P < 0.001; 2- million unlabeled vs. 2- million labeled cells, P < 0.001; 1- million labeled vs. 2- million labeled cells, P < 0.001). C, R2* values 
increased in proportion to the number of labeled NKs included in cell phantoms (agarose vs. 2- million unlabeled cells, P = 0.19; agarose vs. 1- million 
labeled cells, P < 0.001, Agarose vs. 2- million labeled cells, P < 0.001; 2- million unlabeled vs. 1- million labeled cells, P < 0.001; 2- million unlabeled 
vs. 2- million labeled cells, P < 0.001; 1- million labeled vs. 2- million labeled cells, P < 0.001). SNR represents signal- to- noise ratio.
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and IV (P = 0.363). Moreover, there was a strong cor-
relation between tumor ∆R2* at 24 h postinfusion and 
∆volume measurements in IHA group (R2 = 0.704, 
P < 0.001) (Fig. 6B).
Representative CD56 stained slices from tumors 8 days 
after infusion are shown in Figure 6C–E. The quantitative 
measurements of CD56- positive LNKs are shown in Fig 6F. 
There were a significantly larger number of positive- stained 
Figure 5. Quantitative MRI of LNK cell biodistribution in the targeted tumors. A, representative T2W and T2*W images and R2* maps at pre- and 
postinfusion intervals (24 h and 48 h). T2W images at preinfusion, postinfusion 24 h and 48 h are on the top row. T2*W images at preinfusion, 
postinfusion is on the middle row. Quantitative R2*maps at preinfusion, postinfusion 24 h and 48 h are on the bottom row. B, tumor R2* values at 
pre- and postinfusion intervals (each group N = 12) (IHA group: baseline vs. 24 h postinfusion, P = 0.039; baseline vs. 48 h postinfusion, P = 0.019; 
24 h vs. 48 h postinfusion, P = 0.754, control group, baseline vs. 24 h postinfusion, P = 0.741; baseline vs. 48 h postinfusion, P = 0.592; 24 h vs. 48 h 
postinfusion, P = 0.568. IV group, baseline vs. 24 h postinfusion, P = 0.803; baseline vs. 48 h postinfusion, P = 0.694; 24 h vs. 48 h postinfusion, 
P = 0.907). Tumor R2* value at baseline: control vs. IV, P = 0.877; control vs. IHA, P = 0.991; IV vs. IHA, P = 0.9. Tumor R2* value at 24 h postinfusion, 
control vs. IV, P = 0.676; control vs. IHA, P = 0.041; IV vs. IHA, P = 0.023. Tumor R2* value at 48 h postinfusion, control vs. IV, P = 0.719; control vs. 
IHA, P = 0.006; IV vs. IHA, P = 0.006. Circles indicate tumor locations.
A
B
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LNKs measured within tumors for the IHA group than 
for the IV systemic delivery group and control group. 
There were also a significantly larger number of positively 
stained LNKs measured in the IV group than those in 
the control group.
Discussion
Our study demonstrated the following: (1) clinically appli-
cable HPF- labeled NKs can be tracked with MRI, (2) 
transcatheter IHA NK infusion offers the potential to 
radically augment NK cell homing efficiency to liver tumors, 
and (3) the change of tumor R2* value at 24 h postinfu-
sion is an important early biomarker for prediction of 
longitudinal response.
NK- ATI is a promising approach for the treatment of 
solid tumors including HCC [21, 22]. However, conven-
tional intravenous (IV) delivery of NKs may limit the 
number of cells that ultimately reach the target tumor(s) 
and surrounding liver tissues [17, 22, 23]. Because hepatic 
arteries supply ~90% of the blood flow in HCC [24], 
the goal of transcatheter IHA delivery is to selectively 
infuse NKs to targeted HCC lesions for improved thera-
peutic efficacy. Transcatheter IHA infusion methods were 
described in previous studies [17–19] which used human 
NK cell line (NK- 92MI) with FeOlabel Texas Red (Genovis 
AB, Lund, Sweden) nanoparticles labeling. However, 
FeOlabel Texas Red nanoparticles are not approved by 
FDA for clini settings. This study design has a strong 
focus on clinical translation. All methods and materials 
proposed in this study are approved by the FDA for direct 
clinical uses, and our results are directly applicable to 
humans.
Furthermore, in vivo noninvasive tracking of NK cell 
migration to tumors will be critical in predicting early 
therapeutic responses [25–28]. We used a clinically appli-
cable approach of combining FDA- approved drugs to 
form HPF nanocomplexes for magnetic NK labeling so 
that NKs could be visualized by MRI [12, 29]. The HPF 
nanocomplexes have similar biochemical properties to 
iron nanoparticles, which have been used previously to 
label cells through the iron metabolic pathway [12, 29]. 
We optimized the labeling protocol, which showed sig-
nificant uptake of HPF with minimal effect on cell viability 
and cytotoxicity. Our observations were in agreement 
with previous studies [12, 29]. In our study, the doses 
of 50, 100, and 200 μg/mL HPF were used for NK labe-
ling, resulting in high labeling efficiency. However, iron 
uptake per cell was dependent upon HPF concentrations. 
A significant increase in cell death was found in both 
Figure 6. A, graph shows the changes of tumor volumes at 8 days after IHA infusion. Effective inhibition of tumor growth can be observed 8 days 
after IHA infusion (control group vs. IHA group, P < 0.001; IHA group vs. IV group, P = 0.001); no significant difference in therapeutic response was 
observed between control group and IV group 8 days after infusion (P = 0.196). B, graph shows the correlation between the changes of R2* 
measurements at 24 h postinfusion and longitudinal therapeutic response (tumor volume changes) (R2 = 0.704, P < 0.001). B–D, representative CD56 
stained slices from tumors 8 days after infusion (B, control group, C, IV group, and D, IHA group). Dashed line indicates tumor border. E, the 
quantitative measurements of CD56- positive NKs (IHA group vs. IV group, P < 0.0001; IHA group vs. control group, P < 0.0001; IV vs. control, 
P = 0.004). B–D, scale bars = 100 μm.
A C E
B D F
1868 © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
Z. Su et al.MRI- guided NK Cell for Cancer Treatment
100 μg/mL and 200 μg/mL HPF labeling groups when 
compared to the control group. Therefore, the dose of 
50 μg/mL HPH was selected for our study. The 12- h 
labeling time with 50 μg/mL HPf resulted in 87 ± 7% 
labeling efficiency, with no effect on NK cell viability 
and cytotoxicity. This labeling approach and 12- h labeling 
period may be more conducive to clinical translation 
during NK- ATI trials. This limited- duration labeling 
period could potentially avoid NK function alterations 
and cell damage.
In vivo MRI shows extensive HPF- labeled NKs homing 
to the targeted tumor shortly after transcatheter IHA NK 
delivery. A tumor R2* increase was observed within 24 h 
of NK delivery and correlated strongly with therapeutic 
responses (tumor growth inhibition 8 days after NK infu-
sion). Quantification of NK measurements showed that 
the highest amounts of CD56- positive NKs in tumors 
were present in the IHA NK group, while much fewer 
were present in the IV NK group with the least NKs 
evident in the IHA saline group.
Our study had several limitations. MR imaging of HPF- 
labeled NK homing to targeted tumors was performed at 
only two time- points after injection (24 h and 48 h), 
and the study protocol examined only one NK dose that 
was selected from our initial experiences. Additional stud-
ies may be valuable to determine the optimal doses and 
postinjection time intervals for follow- up imaging 
measurements.
In summary, our study demonstrated that (1) NK cells 
labeled with clinically applicable approaches can be tracked 
with MRI, (2) transcatheter IHA NK infusion improves 
NK cell homing efficacy to targeted tumors, and (3) serial 
MRI monitoring of NK cell migration to targeted tumors 
may serve as an important early biomarker for prediction 
of longitudinal response.
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